Growth hormone receptor antagonists
Reading the dates as a sequence: a clerical issue (a withdrawn nomination), a three-week regulatory gap (April 22 to May 5), a clarification, an updated reference document (May 14), and a future PCAC review that will run alongside the broader peptide policy fight already on the agency's calendar
McMackin CJ, et al
Here is the honest evidence status up front: the individual compounds have real human data Tesamorelin is an FDA-approved prescription drug (EGRIFTA) for HIV-associated lipodystrophy, and Ipamorelin has been characterized in human GH-release studies but the fixed Tesamorelin + Ipamorelin blend as sold for research has no completed human randomized controlled trial of its own
This regulatory environment is exactly why working with qualified healthcare providers is so important
This guide focuses on three well-known stores and evaluates them based on pricing, third-party testing transparency, shipping reliability, company maturity, and overall trust signals: LeoLab RX Loti Labs Below, we explore how these vendors stack up and where researchers can find validated alternatives or comparable peptides for metabolic research when NA-931 isnt directly listed